Source: Virtual Congress 2021 – Immunological and molecular characterisation of tuberculosis disease and infection



Rating:

Share or cite this content

Citations should be made in the following way:
J. Bespyatykh (Moscow, Russian Federation). Changes in the metabolism of Mycobacterium tuberculosis during the course of TB treatment. 2477

Member's Comments

No comment yet.

Related content which might interest you: Quantification of long term uptake and metabolism of isoniazid in patients treated for Mycobacterium tuberculosis infection Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities Year: 2009 Pulmonary tuberculosis with primary drug resistant mycobacterium tuberculosis -treatment outcomes Source: Eur Respir J 2004; 24: Suppl. 48, 657s Year: 2004 Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 Mycobacterium tuberculosis resistance Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009 Risk factors for Mycobacterium tuberculosis infection among contacts of pulmonary tuberculosis patients Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Hair-analysis for acetyl-isoniazid/isoniazid ratio and N-acetyl-transferase-2-genotype in patients on treatment for mycobacterium tuberculosis infection Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Considerations upon the drug resistance spectrum of Mycobacterium tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 313s Year: 2001 Discriminating active from latent tuberculosis by Mycobacterium tuberculosis (MTB)-peptide specific immunoresponses Source: Annual Congress 2008 - Priorities for tuberculosis research in Europe: discussing the results of the Tuberculosis Network European Trials Group (TBNET) Year: 2008 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries Source: Eur Respir J 2015; 46: 1563-1576 Year: 2015 Management of latent Mycobacterium tuberculosis infection: WHO guidelines for countries with a low tuberculosis burden Source: International Congress 2016 – ERS publications: a focus on recent guidelines and task forces Year: 2016 Evaluating the non-tuberculous mycobacteria effect in the tuberculosis infection diagnosis Source: Eur Respir J 2010; 35: 338-342 Year: 2010 Drug resistance of Mycobacterium tuberculosis isolated from tuberculosis inflammatory foci Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Mycobacterium tuberculosis resistance profiles in index and secondary TB cases from the same household Source: International Congress 2018 – Challenges in tuberculosis care Year: 2018 Mycobacterium tuberculosis (MTB) content in the air of in-patient facility for the management of pulmonary tuberculosis (TB) Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001 Change of M. tuberculosis drug susceptibility spectrum during chemotherapy Source: Eur Respir J 2006; 28: Suppl. 50, 11s Year: 2006 Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001 Treatment of latent infection with Mycobacterium tuberculosis: update 2010 Source: Eur Respir J 2011; 37: 690-711 Year: 2011